What can we help you find?

April 1, 2016 7:00 am ET

Company Receives EPA Honor for 11th Consecutive Year

Merck (NYSE:MRK), known as MSD outside the United States and Canada,
announced today that it has received an ENERGY STAR 2016 Partner of the
Year – Sustained Excellence Award from the U.S. Environmental Protection
Agency (EPA) for its continued improvement of energy performance and
leadership in energy management in both the pharmaceutical and
industrial sectors.

Merck has been an ENERGY STAR partner since 1995 and recognized by the
EPA for 11 consecutive years, two times as Partner of the Year and now a
ninth time for Sustained Excellence.

“Merck is proud of our partnership with ENERGY STAR, because it helps us
promote our energy program and provides guidance to use energy more
efficiently,” said Don Watson, vice president, Global Workplace &
Enterprise Services, Merck. “We are committed to the efficient use of
our natural resources and reducing the environmental impact of our
operations.”

The award recognizes one Merck manufacturing site that has achieved
ENERGY STAR rankings in the top 25 percent of pharmaceutical plant
energy performance nationwide: Las Piedras, Puerto Rico.

Also achieving certification this year were office buildings in
Cokesbury and Branchburg, N.J., as well as an office building in Upper
Gwynedd, Pa.

“By continued collaboration with ENERGY STAR, Merck is helping Americans
save money, save energy, and do their part to reduce our nation’s
greenhouse gas emissions that exacerbate climate change,” said EPA
Administrator Gina McCarthy. “I’m proud to recognize Merck with the
highest form of ENERGY STAR recognition, as the winner of the 2016
Partner of the Year – Sustained Excellence Award. Merck demonstrates a
strong commitment to energy efficiency and to preserving a healthy
planet for future generations.”

For more information about Merck’s ongoing environmental and energy
conservation efforts, please visit www.merckresponsibility.com.

About ENERGY STAR

ENERGY STAR is the simple choice for energy efficiency. For more than 20
years, people across America have looked to EPA’s ENERGY STAR program
for guidance on how to save energy, save money, and protect the
environment. Behind each blue label is a product, building, or home that
is independently certified to use less energy and cause fewer of the
emissions that contribute to climate change. Today, ENERGY STAR is the
most widely recognized symbol for energy efficiency in the world,
helping families and businesses save $362 billion on utility bills,
while reducing greenhouse gas emissions by more than 2.4 billion metric
tons since 1992. Join the millions who are already making a difference
at energystar.gov.

About Merck

For 125 years, Merck has been a global health care leader working to
help the world be well. Merck is known as MSD outside the United States
and Canada. Through our prescription medicines, vaccines, biologic
therapies, and animal health products, we work with customers and
operate in more than 140 countries to deliver innovative health
solutions. We also demonstrate our commitment to increasing access to
health care through far-reaching policies, programs and partnerships.
For more information, visit www.merck.com
and connect with us on Twitter,
Facebook,
YouTube
and LinkedIn.

Forward-Looking Statement of Merck & Co., Inc., Kenilworth, N.J., USA

This news release of Merck & Co., Inc., Kenilworth, N.J., USA (the
“company”) includes “forward-looking statements” within the meaning of
the safe harbor provisions of the U.S. Private Securities Litigation
Reform Act of 1995. These statements are based upon the current beliefs
and expectations of the company’s management and are subject to
significant risks and uncertainties. If underlying assumptions prove
inaccurate or risks or uncertainties materialize, actual results may
differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry
conditions and competition; general economic factors, including interest
rate and currency exchange rate fluctuations; the impact of
pharmaceutical industry regulation and health care legislation in the
United States and internationally; global trends toward health care cost
containment; technological advances, new products and patents attained
by competitors; challenges inherent in new product development,
including obtaining regulatory approval; the company’s ability to
accurately predict future market conditions; manufacturing difficulties
or delays; financial instability of international economies and
sovereign risk; dependence on the effectiveness of the company’s patents
and other protections for innovative products; and the exposure to
litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events or otherwise. Additional factors that could cause results
to differ materially from those described in the forward-looking
statements can be found in the company’s 2015 Annual Report on Form 10-K
and the company’s other filings with the Securities and Exchange
Commission (SEC) available at the SEC’s Internet site (www.sec.gov).

Media:
Claire Gillespie, 267-305-0932
or
Investors:
Justin Holko, 908-740-1879